利息の受取額、資本剰余金（IFRS）、資本剰余金合計他2件
- 【期間】
| 年度 | 利息の受取額 | 資本剰余金（IFRS） | 資本剰余金合計 | 受取保険金 | 研究開発費 |
|---|
| 2007/03 | - | | - | | 73.5億 | | - | | - | |
| 2008/03 | - | | - | | 73.5億 | ±0% | - | | - | |
| 2009/03 | - | | - | | 73.6億 | +0% | - | | - | |
| 2010/03 | - | | - | | 73.6億 | ±0% | - | | - | |
| 2011/03 | - | | - | | 73.6億 | ±0% | - | | - | |
| 2012/03 | - | | - | | 73.6億 | ±0% | - | | - | |
| 2013/03 | - | | - | | 73.6億 | ±0% | - | | 10.1億 | |
| 2014/03 | - | | - | | 73.6億 | ±0% | - | | 23.5億 | +133.5% |
| 2015/03 | - | | - | | 73.6億 | ±0% | - | | 23.3億 | -0.7% |
| 2016/03 | - | | - | | 73.6億 | ±0% | - | | 25.2億 | +7.9% |
| 2017/03 | - | | - | | 111億 | +50.3% | - | | 24.2億 | -3.9% |
| 2017/12 | - | | 150億 | | 155億 | +39.9% | - | | 23.9億 | -1.4% |
| 2018/12 | 73百万 | | 151億 | +0.3% | 155億 | +0.3% | -640百万 | | 38.7億 | +61.9% |
| 2019/12 | 47百万 | -35.6% | 149億 | -0.9% | 144億 | -7.3% | - | | 34.5億 | -10.8% |
| 2020/12 | 50百万 | +6.4% | 149億 | -0.5% | 152億 | +5.8% | - | | 25.5億 | -26.2% |
| 2021/12 | 35百万 | -30% | 148億 | -0.3% | 152億 | -0.3% | - | | 26.7億 | +4.8% |
| 2022/12 | 69百万 | +97.1% | 148億 | +0.2% | 152億 | ±0% | - | | 35.3億 | +32.2% |
| 2023/12 | 455百万 | +559.4% | 149億 | +0.2% | 152億 | +0.1% | - | | 42.5億 | +20.5% |
